NRX Pharmaceuticals (NRXP) unit Hope Therapeutics said Thursday that it plans to acquire the Kadima Neuropsychiatry Institute.
Hope said Kadima would be the flagship clinic for its planned international network of interventional psychiatry clinics. It also said Kadima founder David Feifel would become Hope's chief medical innovation officer.
Financial terms of the deal were not disclosed.
Shares of NRX Pharmaceuticals were up 11% in recent trading.
Price: 2.45, Change: +0.25, Percent Change: +11.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments